Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial. (linkinghub.elsevier.com)

Authors: Colson AE … Ogbuagu O Journal: The Lancet Published: 2026-08-12 DOI: https://doi.org/10.1016/S0140-6736(26)01442-X